Novel endocrine therapy reduces the risk of breast cancer recurrence

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), when given as an adjuvant therapy for early-stage (1–3) hormone receptor…

Continue Reading

News Source: medicalxpress.com